Research and Reviews: Journal of Pharmacy and Pharmaceutical Sciences

e-ISSN: 2347-226X

p-ISSN: 2319-9857

Adoption of Artificial Intelligence in Biopharm

Priyanka Aswal*

Department of Pharmacy, Uttarakhand Technical University, Uttarakhand, India

Short Communication

Received: 10/07/2021

Accepted: 24/08/2021

Published: 31/08/2021

***For correspondence:**

Priyanka Aswal, Department of Pharmacy, Uttarakhand Technical University, Uttarakhand, India

E-mail: priyankaaswal65@gmail.com

Keywords: Biopharma, Artificial intelligence, Drug discovery

ABSTRACT

Artificial intelligence, predictive, and other superior technologies are speedily being integrated into pharmaceutical companies across the world. The interest in AI-centered solutions for early at the time of drug invention is steadily picking momentum among biopharma in which there is a projected market volume of approximately $10B by 2024 across all AI-driven medical diagnostics, medical imaging, drug discovery, genomics, and personal AI assistants. In the past few years, there has been a tremendous wave of modern R and D partnerships between potential biopharma stakeholders and AI-based corporates, especially the startups. Since the majorities of AI-centered companies maximize various techniques of and use interdisciplinary sources of data in modeling their work, the paper looks into different ways AI can be used in the pharmaceutical industry.

INTRODUCTION

Artificial intelligence, predictive, and other superior technologies are speedily being integrated into pharmaceutical companies across the world. The interest in AI-centered solutions for early at the time of drug invention is steadily picking momentum among biopharma in which there is a projected market volume of approximately $10B by 2024 across all AI-driven medical diagnostics, medical imaging, drug discovery, genomics, and personal AI assistants [1]. In the past few years, there has been a tremendous wave of modern R and D partnerships between potential biopharma stakeholders and AI-based corporates, especially the startups. Since the majority of AI-centered companies maximize various techniques of and use interdisciplinary sources of data in modelling their work, the paper looks into different ways AI can be used in the pharmaceutical industry.

Drug Discovery and Design

Research partnerships with different healthcare facilities have identified and validated novel cancer medication targets relying on simulation AI platforms and casual machine learning [2]. So, AI plays a significant role in the validation and identification of drugs. Some healthcare facilities have AI-driven equipment responsible for the automation of healthcare data and several streams of biomedical information such as next-generation sequencing,

longitudinal electronic medical records, and other 'omic data systems. AI helps in the alteration of these 'omic data into computer models and mechanistic models representing individual patients. Companies can use multi-stage and high interactive drug discovery procedures involving the use of reinforcement learning algorithms and generative adversarial networks. The process involved in AI during drug discovery is elaborated as closed-loop having different stages, among them hypothesis generation, data mining, optimization, and lead compound identification. Such a process allows for careful advancement of the general output prediction outcome over a given duration and with adequate data present.

Furthermore, AI is used in target centered and phenotypic drug discovery using exscientia design by the help of new molecules in the AI-system. The system employs high content screening and phenotypic data as well as examining their potency, binding, and selective affinity regarding certain targets. These projects are massively backed by exscientia enormous data resources from large scale bio-assays and medical chemistry. An outstanding opportunity for AI to get integrated into patient data, biomedical and clinical data is to draw unintuitive concepts regarding drug candidates or even trying to model the entire biological system to identify biomarkers, novel pathways, and targets. Companies can also use real-world biomedical data like the expression of gene measurements, clinical records, and protein interaction sequences. By assessing billion of series of data, companies dealing pharma and biomedical structures will be able to dissociate relevant and irrelevant processes hence leading to the effectiveness of particular small molecules.

DISCUSSION

Manufacturing Process Improvement

The adoption of AI in the biopharmaceutical industry can assist in improving the manufacturing process in development and production. AI can execute quality control, reduce wastage of materials, shorten design perform predictive maintenance, and advance production reuse [3]. Also, AI can be adopted in various ways to increase the efficiency of the production process with higher output and reduce wastage of materials. Many clinical studies depend on paper and manual diaries in which patients are expected to log every time they a drug, what other types of medications they use as well as different severe reactions these medications may cause. Everything appears handwritten notes, and the test outcomes concerning the environmental factors and the imaging scans can be gathered and interpreted using AI.

Processing Biomedical and Clinical Data

Numerous cognizant studies have demonstrated that about 80 percent of all clinical trials fail to satisfy enrollment timelines and enrollment challenges cause approximately a third of all phase three clinical study terminations [4]. Rare diseases and individualized medicine can be achieved through the adoption of AI. Incorporating information from analytics, body scans, and patient biology AI can be used to detect various ailments such as cancer and prediction of health challenges people might encounter as a result of their genetics [5]. These advancements can use every patient's medical data and history to recommend personalized treatment schedules. The development of personalized drug treatments can be accomplished through AI to test results, reactions to previous medications as well as historical patient information for drug responses.

CONCLUSION

In conclusion, the identification of clinical trials can also succeed through the adoption of AI. Other than assisting in creating a sense of clinical trial data, another way the adoption of AI can help in the pharmaceutical sector is locating patients to take part in trials. With the help of advanced predictive analytics, AI can be used in the analysis of genetic information to know the specific patient population suitable for use in the trials as well as determining the optimal sample size. Modern AI technology can interpret read free-form text that patients give during clinical trial procedures and unstructured data like intake documents and physician's notes. Is it believed that a staggering 86 percent of all the trials that take place in clinics during the recruitment of sufficient patients fail? Consequentially, slower research, and patients' delays in accessing life savings drugs become the outcome. Therefore, AI can be adopted to enhance predictions of treatment results as well as predictive biomarkers.

REFERENCES

1. Shah P, et al. Artificial intelligence and machine learning in clinical development: A translational perspective. NPJ Digital Med. 2019;2:1-5.
2. Probst C, et al. Advanced characterization of silicone oil droplets in protein therapeutics using artificial intelligence analysis of imaging flow cytometry data. J Pharm Sci. 2020;109:2996-3005.
3. Rowe RC, et al. Artificial intelligence in pharmaceutical product formulation: Knowledge-based and expert systems. Phar Sci Technol Today. 1998;1:153-159.
4. Egorov E, et al. Robotics, microfluidics, nanotechnology and AI in the synthesis and evaluation of liposomes and polymeric drug delivery systems. Drug Delivery Translational Res. 2021;11:345-352.
5. Zhu Z, et al. 3D-printed multifunctional materials enabled by artificial-intelligence-assisted fabrication technologies. Nature Reviews Materials. 2021;6:27-47.